Human Immunodeficiency Virus Type 1 env Clones from Acute and Early Subtype B Infections for Standardized Assessments of Vaccine-Elicited Neutralizing Antibodies
暂无分享,去创建一个
Xiping Wei | Feng Gao | John R. Mascola | David C. Montefiori | J. Mascola | L. Stamatatos | D. Montefiori | B. Hahn | Xiping Wei | P. Gilbert | P. Goepfert | J. Salazar-Gonzalez | J. Decker | V. Polonis | Kelli Greene | F. Gao | M. Koutsoukos | Denise L. Kothe | Miroslawa Bilska | Kelli M. Greene | Julie M. Decker | Beatrice H. Hahn | G. Voss | Jesus F. Salazar-Gonzalez | Ming Li | M. Bilska | Peter Gilbert | Paul Goepfert | Leonidas Stamatatos | Gerald Voss | Victoria R. Polonis | Ming Li | Marguerite Koutsoukos | F. Gao | K. Greene
[1] I. Berkower,et al. Assembly, structure, and antigenic properties of virus-like particles rich in HIV-1 envelope gp120. , 2004, Virology.
[2] Renate Kunert,et al. Comprehensive Cross-Clade Neutralization Analysis of a Panel of Anti-Human Immunodeficiency Virus Type 1 Monoclonal Antibodies , 2004, Journal of Virology.
[3] W. Blattner,et al. A distinctive clade B HIV type 1 is heterosexually transmitted in Trinidad and Tobago. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[4] E. Coligan. Current protocols in immunology , 1991 .
[5] Gennaro Ciliberto,et al. Structural analysis of the epitope of the anti-HIV antibody 2F5 sheds light into its mechanism of neutralization and HIV fusion. , 2003, Journal of molecular biology.
[6] M. Cho,et al. Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies. , 2003, Virology.
[7] D R Burton,et al. Synergistic neutralization of a chimeric SIV/HIV type 1 virus with combinations of human anti-HIV type 1 envelope monoclonal antibodies or hyperimmune globulins. , 1997, AIDS research and human retroviruses.
[8] G Himmler,et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1 , 1993, Journal of virology.
[9] Yang Liu,et al. Characterization of Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Variation and Neutralizing Antibody Responses during Transmission of HIV-1 Subtype B , 2005, Journal of Virology.
[10] D R Burton,et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. , 1994, Science.
[11] J. Mascola,et al. The Ability of an Oligomeric Human Immunodeficiency Virus Type 1 (HIV-1) Envelope Antigen To Elicit Neutralizing Antibodies against Primary HIV-1 Isolates Is Improved following Partial Deletion of the Second Hypervariable Region , 2001, Journal of Virology.
[12] J. Felsenstein. CONFIDENCE LIMITS ON PHYLOGENIES: AN APPROACH USING THE BOOTSTRAP , 1985, Evolution; international journal of organic evolution.
[13] H. Katinger,et al. Immunogenic presentation of a conserved gp41 epitope of human immunodeficiency virus type 1 on recombinant surface antigen of hepatitis B virus. , 1996, The Journal of general virology.
[14] C. E. Parker,et al. Fine Definition of the Epitope on the gp41 Glycoprotein of Human Immunodeficiency Virus Type 1 for the Neutralizing Monoclonal Antibody 2F5 , 2001, Journal of Virology.
[15] J. Sodroski,et al. Characterization of Simian-Human Immunodeficiency Virus Envelope Glycoprotein Epitopes Recognized by Neutralizing Antibodies from Infected Monkeys , 1998, Journal of Virology.
[16] H. Liao,et al. Comparison of HIV Type 1 ADA gp120 monomers versus gp140 trimers as immunogens for the induction of neutralizing antibodies. , 2005, AIDS research and human retroviruses.
[17] John P. Moore,et al. Urgently needed: a filter for the HIV-1 vaccine pipeline , 2004, Nature Medicine.
[18] D R Burton,et al. Potent neutralization of primary human immunodeficiency virus clade C isolates with a synergistic combination of human monoclonal antibodies raised against clade B. , 2001, Journal of human virology.
[19] B. Wahrén,et al. Enhanced immunogenicity of a human immunodeficiency virus type 1 env DNA vaccine by manipulating N-glycosylation signals. Effects of elimination of the V3 N306 glycan. , 2001, Vaccine.
[20] J. Sodroski,et al. Antibody cross-competition analysis of the human immunodeficiency virus type 1 gp120 exterior envelope glycoprotein , 1996, Journal of virology.
[21] J. Nielsen,et al. Resistance to V3-directed neutralization caused by an N-linked oligosaccharide depends on the quaternary structure of the HIV-1 envelope oligomer. , 1996, Virology.
[22] Q. Sattentau,et al. Inactivation of Human Immunodeficiency Virus Type 1 Infectivity with Preservation of Conformational and Functional Integrity of Virion Surface Proteins , 1998, Journal of Virology.
[23] J. Weber,et al. Comparison of the Antibody Repertoire Generated in Healthy Volunteers following Immunization with a Monomeric Recombinant gp120 Construct Derived from a CCR5/CXCR4-Using Human Immunodeficiency Virus Type 1 Isolate with Sera from Naturally Infected Individuals , 1999, Journal of Virology.
[24] Bette T. Korber,et al. Antigenicity and Immunogenicity of a Synthetic Human Immunodeficiency Virus Type 1 Group M Consensus Envelope Glycoprotein , 2005, Journal of Virology.
[25] D. Montefiori,et al. Immunization with recombinant canarypox vectors expressing membrane-anchored glycoprotein 120 followed by glycoprotein 160 boosting fails to generate antibodies that neutralize R5 primary isolates of human immunodeficiency virus type 1. , 2000, AIDS research and human retroviruses.
[26] James E. K. Hildreth,et al. Antibody to adhesion molecule LFA-1 enhances plasma neutralization of human immunodeficiency virus type 1 , 1995, Journal of virology.
[27] J. Goudsmit,et al. An N-glycan within the human immunodeficiency virus type 1 gp120 V3 loop affects virus neutralization. , 1994, Virology.
[28] A. Fauci,et al. Selection of HIV-specific immunogenic epitopes by screening random peptide libraries with HIV-1-positive sera. , 1999, Journal of immunology.
[29] J. Sodroski,et al. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization , 1997, Journal of virology.
[30] D. Ho,et al. DNA Vaccination with the Human Immunodeficiency Virus Type 1 SF162ΔV2 Envelope Elicits Immune Responses That Offer Partial Protection from Simian/Human Immunodeficiency Virus Infection to CD8+ T-Cell-Depleted Rhesus Macaques , 2001, Journal of Virology.
[31] H. Schuitemaker,et al. Adaptation to persistent growth in the H9 cell line renders a primary isolate of human immunodeficiency virus type 1 sensitive to neutralization by vaccine sera , 1995, Journal of virology.
[32] S. Osmanov,et al. Serotyping of HIV type 1 infections: definition, relationship to viral genetic subtypes, and assay evaluation. UNAIDS Network for HIV-1 Isolation and Characterization. , 1998, AIDS research and human retroviruses.
[33] S. Zolla-Pazner,et al. Additive Effects Characterize the Interaction of Antibodies Involved in Neutralization of the Primary Dualtropic Human Immunodeficiency Virus Type 1 Isolate 89.6 , 2001, Journal of Virology.
[34] Ping Zhu,et al. Antibody Domain Exchange Is an Immunological Solution to Carbohydrate Cluster Recognition , 2003, Science.
[35] N. Saitou,et al. The neighbor-joining method: a new method for reconstructing phylogenetic trees. , 1987, Molecular biology and evolution.
[36] R. Means,et al. A role for carbohydrates in immune evasion in AIDS , 1998, Nature Medicine.
[37] J. Mascola,et al. HIV-1 envelope pseudotyped viral vectors and infectious molecular clones expressing the same envelope glycoprotein have a similar neutralization phenotype, but culture in peripheral blood mononuclear cells is associated with decreased neutralization sensitivity. , 2005, Virology.
[38] Jamie K. Scott,et al. Identification and Characterization of a Peptide That Specifically Binds the Human, Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody b12 , 2001, Journal of Virology.
[39] J. Sodroski,et al. Molecular cloning and analysis of functional envelope genes from human immunodeficiency virus type 1 sequence subtypes A through G. The WHO and NIAID Networks for HIV Isolation and Characterization , 1996, Journal of virology.
[40] J. Binley,et al. Variable-Loop-Deleted Variants of the Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Can Be Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits , 2000, Journal of Virology.
[41] S. Zolla-Pazner,et al. The cross-clade neutralizing activity of a human monoclonal antibody is determined by the GPGR V3 motif of HIV type 1. , 2004, AIDS research and human retroviruses.
[42] A. Trkola,et al. A broadly neutralizing human monoclonal antibody against gp41 of human immunodeficiency virus type 1. , 1994, AIDS research and human retroviruses.
[43] Susan Zolla-Pazner,et al. Synergistic Neutralization of Simian-Human Immunodeficiency Virus SHIV-vpu+ by Triple and Quadruple Combinations of Human Monoclonal Antibodies and High-Titer Anti-Human Immunodeficiency Virus Type 1 Immunoglobulins , 1998, Journal of Virology.
[44] John R. Mascola,et al. Immunogenicity of Constrained Monoclonal Antibody A32-Human Immunodeficiency Virus (HIV) Env gp120 Complexes Compared to That of Recombinant HIV Type 1 gp120 Envelope Glycoproteins , 2004, Journal of Virology.
[45] J. Mascola,et al. HIV-1: nature's master of disguise , 2003, Nature Medicine.
[46] L. Stamatatos,et al. Effect of major deletions in the V1 and V2 loops of a macrophage-tropic HIV type 1 isolate on viral envelope structure, cell entry, and replication. , 1998, AIDS research and human retroviruses.
[47] Feng Gao,et al. Viremia Control Despite Escape from a Rapid and Potent Autologous Neutralizing Antibody Response After Therapy Cessation in an HIV-1-Infected Individual 1 , 2003, The Journal of Immunology.
[48] S. J. Clark,et al. High titers of cytopathic virus in plasma of patients with symptomatic primary HIV-1 infection. , 1991, The New England journal of medicine.
[49] D. Montefiori,et al. Polyvalent Envelope Glycoprotein Vaccine Elicits a Broader Neutralizing Antibody Response but Is Unable To Provide Sterilizing Protection against Heterologous Simian/Human Immunodeficiency Virus Infection in Pigtailed Macaques , 2001, Journal of Virology.
[50] D. Montefiori,et al. Prospects for vaccine protection against HIV-1 infection and AIDS. , 2002, Annual review of immunology.
[51] E. Sanders-Buell,et al. Biologic and Genetic Characterization of a Panel of 60 Human Immunodeficiency Virus Type 1 Isolates, Representing Clades A, B, C, D, CRF01_AE, and CRF02_AG, for the Development and Assessment of Candidate Vaccines , 2005, Journal of Virology.
[52] J. Sodroski,et al. The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens. , 1998, Science.
[53] C. Fox,et al. Evolutionary pattern of human immunodeficiency virus (HIV) replication and distribution in lymph nodes following primary infection: Implications for antiviral therapy , 1998, Nature Medicine.
[54] Desmond G. Higgins,et al. Fast and sensitive multiple sequence alignments on a microcomputer , 1989, Comput. Appl. Biosci..
[55] J. Shendure,et al. Epitope insertion into variable loops of HIV-1 gp120 as a potential means to improve immunogenicity of viral envelope protein. , 1999, Vaccine.
[56] J. Mascola,et al. Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12 , 1997, Journal of virology.
[57] Dennis R. Burton,et al. Hyperglycosylated Mutants of Human Immunodeficiency Virus (HIV) Type 1 Monomeric gp120 as Novel Antigens for HIV Vaccine Design , 2003, Journal of Virology.
[58] J. Thompson,et al. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.
[59] E. Rosenberg,et al. Immune control of HIV-1 after early treatment of acute infection , 2000, Nature.
[60] C. Cheng‐Mayer,et al. Antibody Protects Macaques against Vaginal Challenge with a Pathogenic R5 Simian/Human Immunodeficiency Virus at Serum Levels Giving Complete Neutralization In Vitro , 2001, Journal of Virology.
[61] C Leclerc,et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. , 2000, Vaccine.
[62] P. Nara,et al. Human Immunodeficiency Virus (HIV)-Positive Sera Obtained Shortly after Seroconversion Neutralize Autologous HIV Type 1 Isolates on Primary Macrophages but Not on Lymphocytes , 2000, Journal of Virology.
[63] X. Yu,et al. Mutational analysis of conserved N-linked glycosylation sites of human immunodeficiency virus type 1 gp41 , 1992, Journal of virology.
[64] P. Earl,et al. Immunogenicity and Protective Efficacy of Oligomeric Human Immunodeficiency Virus Type 1 gp140 , 2001, Journal of Virology.
[65] J. Sodroski,et al. Modifications That Stabilize Human Immunodeficiency Virus Envelope Glycoprotein Trimers in Solution , 2000, Journal of virology.
[66] Lynn Morris,et al. Recommendations for the Design and Use of Standard Virus Panels To Assess Neutralizing Antibody Responses Elicited by Candidate Human Immunodeficiency Virus Type 1 Vaccines , 2005, Journal of Virology.
[67] M. Tremblay,et al. The acquisition of host-encoded proteins by nascent HIV-1. , 1998, Immunology today.
[68] D. Montefiori,et al. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay , 1988, Journal of clinical microbiology.
[69] B. Walker,et al. Techniques in HIV Research , 1990, Palgrave Macmillan UK.
[70] J. Sodroski,et al. Characterization of Stable, Soluble Trimers Containing Complete Ectodomains of Human Immunodeficiency Virus Type 1 Envelope Glycoproteins , 2000, Journal of Virology.
[71] D. Montefiori,et al. Induction of Neutralizing Antibodies and Gag-Specific Cellular Immune Responses to an R5 Primary Isolate of Human Immunodeficiency Virus Type 1 in Rhesus Macaques , 2001, Journal of Virology.
[72] John P. Moore,et al. Use of Inhibitors To Evaluate Coreceptor Usage by Simian and Simian/Human Immunodeficiency Viruses and Human Immunodeficiency Virus Type 2 in Primary Cells , 2000, Journal of Virology.
[73] G. McGaughey,et al. HIV-1 vaccine development: constrained peptide immunogens show improved binding to the anti-HIV-1 gp41 MAb. , 2003, Biochemistry.
[74] Dorothy M. Lang,et al. Selection for Human Immunodeficiency Virus Type 1 Envelope Glycosylation Variants with Shorter V1-V2 Loop Sequences Occurs during Transmission of Certain Genetic Subtypes and May Impact Viral RNA Levels , 2005, Journal of Virology.
[75] D. Ho,et al. Transient high levels of viremia in patients with primary human immunodeficiency virus type 1 infection. , 1991, The New England journal of medicine.
[76] D. Montefiori,et al. Crosslinked HIV-1 envelope–CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[77] J. Rose,et al. Role of N-Linked Glycans in a Human Immunodeficiency Virus Envelope Glycoprotein: Effects on Protein Function and the Neutralizing Antibody Response , 2002, Journal of Virology.
[78] T. Schacker,et al. Clinical and Epidemiologic Features of Primary HIV Infection , 1996, Annals of Internal Medicine.
[79] Adeeba Kamarulzaman,et al. AIDS Res Hum Retroviruses , 2006 .
[80] Wayne C Koff,et al. HIV vaccine design and the neutralizing antibody problem , 2004, Nature Immunology.
[81] Paul W. H. I. Parren,et al. Broadly Neutralizing Antibodies Targeted to the Membrane-Proximal External Region of Human Immunodeficiency Virus Type 1 Glycoprotein gp41 , 2001, Journal of Virology.
[82] D. Montefiori,et al. Neutralizing antibody responses to human immunodeficiency virus type 1 in primary infection and long-term-nonprogressive infection. , 1997, The Journal of infectious diseases.
[83] M. Reitz,et al. Expression and Characterization of a Single-Chain Polypeptide Analogue of the Human Immunodeficiency Virus Type 1 gp120-CD4 Receptor Complex , 2000, Journal of Virology.
[84] J. Kappes,et al. Emergence of Resistant Human Immunodeficiency Virus Type 1 in Patients Receiving Fusion Inhibitor (T-20) Monotherapy , 2002, Antimicrobial Agents and Chemotherapy.
[85] H. Katinger,et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. , 2001, AIDS research and human retroviruses.
[86] K. Komuro,et al. Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses. , 2004, Virology.
[87] B. Haynes,et al. Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. , 1984, Science.
[88] J. Mascola,et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies , 2000, Nature Medicine.
[89] Martin A. Nowak,et al. Antibody neutralization and escape by HIV-1 , 2003, Nature.
[90] Feng Gao,et al. Diversity Considerations in HIV-1 Vaccine Selection , 2002, Science.
[91] F. Graham,et al. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. , 1977, The Journal of general virology.
[92] D R Burton,et al. Human immunodeficiency virus type 1 mutants that escape neutralization by human monoclonal antibody IgG1b12. off , 1997, Journal of virology.
[93] B. Chesebro,et al. Effects of CCR5 and CD4 Cell Surface Concentrations on Infections by Macrophagetropic Isolates of Human Immunodeficiency Virus Type 1 , 1998, Journal of Virology.
[94] Abraham Pinter,et al. Human Monoclonal Antibodies Specific for Conformation-Sensitive Epitopes of V3 Neutralize Human Immunodeficiency Virus Type 1 Primary Isolates from Various Clades , 2002, Journal of Virology.
[95] H. Katinger,et al. Complete protection of neonatal rhesus macaques against oral exposure to pathogenic simian-human immunodeficiency virus by human anti-HIV monoclonal antibodies. , 2004, The Journal of infectious diseases.
[96] M. Bergeron,et al. Interaction between virion-bound host intercellular adhesion molecule-1 and the high-affinity state of lymphocyte function-associated antigen-1 on target cells renders R5 and X4 isolates of human immunodeficiency virus type 1 more refractory to neutralization. , 2000, Virology.
[97] John P. Moore,et al. Stabilization of the Soluble, Cleaved, Trimeric Form of the Envelope Glycoprotein Complex of Human Immunodeficiency Virus Type 1 , 2002, Journal of Virology.
[98] H. Kiyono,et al. HIV Mucosal Vaccine: Nasal Immunization with gp160-Encapsulated Hemagglutinating Virus of Japan-Liposome Induces Antigen-Specific CTLs and Neutralizing Antibody Responses1 , 2003, The Journal of Immunology.
[99] L. Stamatatos,et al. Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate , 2003, Journal of Virology.
[100] L. Sawyer,et al. Neutralization sensitivity of human immunodeficiency virus type 1 is determined in part by the cell in which the virus is propagated , 1994, Journal of virology.
[101] Roy E. Byington,et al. Quantitative Assays for Virus Infectivity , 1990 .
[102] Lawrence Corey,et al. Biological and Virologic Characteristics of Primary HIV Infection , 1998, Annals of Internal Medicine.
[103] F. Vannberg,et al. Human Immunodeficiency Virus Type 1 Subtype C Molecular Phylogeny: Consensus Sequence for an AIDS Vaccine Design? , 2002, Journal of Virology.
[104] P. Berman,et al. Cryptic nature of envelope V3 region epitopes protects primary monocytotropic human immunodeficiency virus type 1 from antibody neutralization , 1994, Journal of virology.
[105] D. Montefiori,et al. Evaluating Neutralizing Antibodies Against HIV, SIV, and SHIV in Luciferase Reporter Gene Assays , 2004, Current protocols in immunology.
[106] Paul W. H. I. Parren,et al. Fine Mapping of the Interaction of Neutralizing and Nonneutralizing Monoclonal Antibodies with the CD4 Binding Site of Human Immunodeficiency Virus Type 1 gp120 , 2003, Journal of Virology.
[107] N. Haigwood,et al. Neutralizing antibody directed against the HIV–1 envelope glycoprotein can completely block HIV–1/SIV chimeric virus infections of macaque monkeys , 1999, Nature Medicine.
[108] John R Mascola,et al. Defining the protective antibody response for HIV-1. , 2003, Current molecular medicine.
[109] S. Zolla-Pazner,et al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody , 1992, Journal of virology.
[110] J. Sodroski,et al. Solid-Phase Proteoliposomes Containing Human Immunodeficiency Virus Envelope Glycoproteins , 2002, Journal of Virology.
[111] J. Mascola,et al. The V3 Loop Is Accessible on the Surface of Most Human Immunodeficiency Virus Type 1 Primary Isolates and Serves as a Neutralization Epitope , 2004, Journal of Virology.
[112] J. Mascola,et al. Protection of Macaques against Pathogenic Simian/Human Immunodeficiency Virus 89.6PD by Passive Transfer of Neutralizing Antibodies , 1999, Journal of Virology.
[113] D. Montefiori,et al. Induction of immune responses to HIV‐1 by canarypox virus (ALVAC) HIV‐1 and gp120 SF‐2 recombinant vaccines in uninfected volunteers , 1998, AIDS.
[114] J. Jurka,et al. Multiple aligned sequence editor (MASE). , 1988, Trends in biochemical sciences.
[115] Bette T. Korber,et al. Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission , 2004, Science.
[116] J. Levy,et al. Isolation of lymphocytopathic retroviruses from San Francisco patients with AIDS. , 1984, Science.
[117] L. Stamatatos,et al. Changes in the Immunogenic Properties of Soluble gp140 Human Immunodeficiency Virus Envelope Constructs upon Partial Deletion of the Second Hypervariable Region , 2003, Journal of Virology.
[118] A. Trkola,et al. A luciferase-reporter gene-expressing T-cell line facilitates neutralization and drug-sensitivity assays that use either R5 or X4 strains of human immunodeficiency virus type 1. , 2001, Virology.
[119] Raghavan Varadarajan,et al. Characterization of gp120 and Its Single-Chain Derivatives, gp120-CD4D12 and gp120-M9: Implications for Targeting the CD4i Epitope in Human Immunodeficiency Virus Vaccine Design , 2005, Journal of Virology.
[120] J. Binley,et al. A Recombinant Human Immunodeficiency Virus Type 1 Envelope Glycoprotein Complex Stabilized by an Intermolecular Disulfide Bond between the gp120 and gp41 Subunits Is an Antigenic Mimic of the Trimeric Virion-Associated Structure , 2000, Journal of Virology.
[121] J. Mascola,et al. Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Evaluation Group. , 1996, The Journal of infectious diseases.
[122] J. Lifson,et al. Chemical inactivation of retroviral infectivity by targeting nucleocapsid protein zinc fingers: a candidate SIV vaccine. , 1998, AIDS research and human retroviruses.
[123] H. Katinger,et al. The Broadly Neutralizing Anti-Human Immunodeficiency Virus Type 1 Antibody 2G12 Recognizes a Cluster of α1→2 Mannose Residues on the Outer Face of gp120 , 2002, Journal of Virology.
[124] G. de Thé,et al. Immunogenicity and Protective Efficacy of Recombinant Human T-Cell Leukemia/Lymphoma Virus Type 1 NYVAC and Naked DNA Vaccine Candidates in Squirrel Monkeys (Saimiri sciureus) , 2001, Journal of Virology.
[125] Peter D. Kwong,et al. The Mannose-Dependent Epitope for Neutralizing Antibody 2G12 on Human Immunodeficiency Virus Type 1 Glycoprotein gp120 , 2002, Journal of Virology.
[126] M. Kimura. A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences , 1980, Journal of Molecular Evolution.
[127] Peter D. Kwong,et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites , 2002, Nature.
[128] L. Stamatatos,et al. Macrophage tropism of human immunodeficiency virus type 1 and utilization of the CC-CKR5 coreceptor , 1997, Journal of virology.
[129] J. Shiver,et al. Enhancement of α-Helicity in the HIV-1 Inhibitory Peptide DP178 Leads to an Increased Affinity for Human Monoclonal Antibody 2F5 but Does Not Elicit Neutralizing Responses in Vitro , 2002, The Journal of Biological Chemistry.